SuperworthBioCardia EPS BCDA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Mar 31, 2026
- n/m
- a quarter missing
- Latest quarter, Q1 FY26
- −$0.21
- Fiscal year 2021
- −$11.10
BioCardia's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q1 FY26, it was −$0.21.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$11.10 | n/a |
| FY2020 | −$24.90 | n/a |
| FY2019 | −$41.70 | n/a |
| FY2018 | −$48.75 | n/a |
| FY2017 | −$44.55 | n/a |
| FY2015 | $0.00 | n/a |
| FY2014 | $0.00 | n/a |
| FY2013 | $0.00 | n/a |
| FY2012 | $0.00 | −100% |
| FY2011 | $162.00 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY26 | −$0.21 | n/a | n/a | |
| Q2 FY25 | −$0.40 | n/a | n/a | |
| Q1 FY25 | −$0.59 | n/a | n/a | |
| Q4 FY21 | −$3.00 | n/a | −$11.10 | |
| Q3 FY21 | −$2.40 | n/a | −$11.55 | |
| Q2 FY21 | −$3.00 | n/a | −$13.65 | |
| Q1 FY21 | −$2.70 | n/a | −$17.55 | |
| Q4 FY20 | −$3.45 | n/a | −$24.90 | |
| Q3 FY20 | −$4.50 | n/a | −$29.25 | |
| Q2 FY20 | −$6.90 | n/a | −$34.20 | |
| Q1 FY20 | −$10.05 | n/a | −$38.85 | |
| Q4 FY19 | −$7.80 | n/a | −$41.70 |
Against its peers
Companies in Healthcare nearest BioCardia's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BCDABioCardia | n/m | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BioCardia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.